This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Oncology Resources

Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links to find further resources on key clinical data for afatinib and nintedanib, and the latest information on tumour types in which clinical investigations have been done or are ongoing.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.